 |
|
|
| |
Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials
|
| |
| |
EASL: Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial - (04/24/15)
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Didier Samuel,1 Michael Manns,2 Xavier Forns,3 Steven L. Flamm,4 K. Rajender Reddy,5 Jill Denning,6 Sarah Arterburn,6 Theo Brandt-Sarif,6 Phillip S. Pang,6 John G. McHutchison,6 Nezam Afdhal,7 Michael Charlton,8 Edward Gane,9 David Mutimer,10 Gregory T. Everson11
1Université Paris-Sud, Villejuif, France; 2Hannover Medical School, Hannover, Germany; 3Liver Unit, IDIBAPS, CIBEREHD Hospital Clinic, Barcelona, Spain; 4Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; 5University of Pennsylvania School of Medicine, Philadelphia, Pennslvania, USA; 6Gilead Sciences, Inc., Foster City, California, USA; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 8Intermountain Medical Center, Murray, Utah, USA; 9University of Auckland, New Zealand; 10Queen Elizabeth Hospital and University of Birmingham, Birmingham, England; 11University of Colorado Denver, Aurora, Colorado, USA
|
| |
|
|
|
|
|
